Category: Blackstone
Sanofi has agreed a deal with life sciences investor Blackstone to help fund clinical trials of a new formulation of Sarclisa for blood cancer multiple myeloma, accelerating its development. Blackstone will provide €300 million in funding for the project, which will focus on a subcutaneous formulation of Sarclisa (carfilzomib) that is due to start a […]
Private equity firm Blackstone has agreed to provide up to $250 million in financing to UK biotech Autolus Therapeutics, to help it take acute lymphoblastic leukaemia (ALL) CAR-T therapy obe-cel through late-stage development. The deal includes a $100 million equity stake, $50 million in financing as soon as it closes, and another $100 million on […]
After more than doubling its patient volumes during the pandemic, Carbon Health raised funding to further its growth plans. The company said it plans to open 1,500 clinics by 2025.
The new joint venture will bring K Health’s artificial intelligence-driven technology to the consumer, employer and insurer markets. The solution enables patients to understand their symptoms and connect with a doctor if needed.
The San Francisco-based company aims to complete at least one Phase III study by 2025, and it is weighing an IPO next year to fund more.
Takeda has joined the ranks of big pharma companies jettisoning consumer health businesses in order to concentrate on higher-margin prescription drugs. The drugmaker is divesting Takeda Consumer Healthcare, which operates mainly in Japan, to private equity group Blackstone for 242 billion yen ($2.3 billion), with the deal expected to close in March of next year. […]
Shots: Takeda and Blackstone sign an agreement to divest it consumer health care business unit for $2.3B. The transaction expected to be closed by Mar 31, 2021 The portfolio to be divested includes OTC medicines and health products along with its lead product in the region, Alinamin. Blackstone plans to develop the business together with […]
Ancestry, which grew from a genealogy tracking tool to offering DNA tests for a number of healthconditions, reached a deal to be acquired by Blackstone for $4.7 billion. But privacy advocates have raised concerns over the deal — namely, what would happen to users’ health data?